Sugi Predict

Sugi Predict / Compounds / SCHEMBL5529701

SCHEMBL5529701

SCHEMBL5529701

COCCOCCOC(=O)NC(COCCOC)C(=O)NCC(=O)NC1C(O)CC(OC=O)(OC(C)C)OC1C(O)C(O)CO

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CD22 P20273 14/20 0.33
▸ MAG P20916 3/20 0.31
▸ PSMB11 A5LHX3 1/20 0.30
▸ PSMA7 O14818 1/20 0.30
▸ PSMB1 P20618 1/20 0.30
▸ PSMA1 P25786 1/20 0.30
▸ PSMA2 P25787 1/20 0.30
▸ PSMA3 P25788 1/20 0.30
▸ PSMA4 P25789 1/20 0.30
▸ PSMB8 P28062 1/20 0.30
▸ PSMB9 P28065 1/20 0.30
▸ PSMA5 P28066 1/20 0.30
▸ PSMB4 P28070 1/20 0.30
▸ PSMB6 P28072 1/20 0.30
▸ PSMB5 P28074 1/20 0.30
▸ PSMB10 P40306 1/20 0.30
▸ PSMB3 P49720 1/20 0.30
▸ PSMB2 P49721 1/20 0.30
▸ PSMA6 P60900 1/20 0.30
▸ PSMA8 Q8TAA3 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17083471 0.97 CD22 (0.32) CD22
SCHEMBL10260947 0.92 CD22 (0.35) CD22MAG
SCHEMBL5529719 0.91 CD22 (0.33) CD22
SCHEMBL5533916 0.91 CD22 (0.34) CD22
SCHEMBL17083472 0.90 CD22 (0.34) CD22
SCHEMBL17083475 0.89 CD22 (0.32) CD22
SCHEMBL12341459 0.87 NANP (0.39) CD22MAG
SCHEMBL5532089 0.86 NANP (0.35) CD22MAG
SCHEMBL13402333 0.85 CD22 (0.38) CD22
SCHEMBL5531719 0.83 CD22 (0.36) CD22

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170281785-A1 GLYCEROL LINKED PEGYLATED SUGARS AND GLYCOPEPTIDES NOVO NORDISK A/S (DK) 2017-10-05 — — US disclosed
US-20170136104-A1 GLYCOPEGYLATED FACTOR IX NOVO NORDISK AS (DK) 2017-05-18 — — US disclosed
US-20160361427-A1 Glycopegylated Factor IX NOVO NORDISK AS (DK) 2016-12-15 — — US disclosed
US-20160184412-A1 Glycopegylated Factor IX NOVO NORDISK AS (DK) 2016-06-30 — — US disclosed
US-20160158319-A1 REMODELING AND GLYCOPEGYLATION OF FIBROBLAST GROWTH FACTOR (FGF) NOVO NORDISK A/S (DK) 2016-06-09 — — US disclosed
US-9200049-B2 Remodeling and glycopegylation of fibroblast growth factor (FGF) NOVO NORDISK A/S (DK) 2015-12-01 — — US disclosed
US-20150125437-A1 Glycopegylated Factor IX NOVO NORDISK AS (DK) 2015-05-07 — — US disclosed
US-8916360-B2 Glycopegylated erythropoietin NOVO NORDISK A/S (DK) 2014-12-23 — — US disclosed
US-8791070-B2 Glycopegylated factor IX NOVO NORDISK A/S (DK) 2014-07-29 — — US disclosed
US-8791066-B2 Branched PEG remodeling and glycosylation of glucagon-like peptide-1 [GLP-1] NOVO NORDISK A/S (DK) 2014-07-29 — — US disclosed
US-20140112903-A1 Glycopegylated Factor IX NOVO NORDISK A/S (DK) 2014-04-24 — — US disclosed
US-8633157-B2 Glycopegylated erythropoietin NOVO NORDISK A/S (DK) 2014-01-21 — — US disclosed
US-8632770-B2 Glycopegylated factor IX NOVO NORDISK A/S (DK) 2014-01-21 — — US disclosed
US-20130137157-A1 GLYCOPEGYLATED FACTOR VII AND FACTOR VIIA NOVO NORDISK A/S (DK) 2013-05-30 — — US disclosed
US-20130059780-A1 BRANCHED PEG REMODELING AND GLYCOSYLATION OF GLUCAGON-LIKE PEPTIDE-1 [GLP-1] BIOGENERIX AG (DE) 2013-03-07 — — US disclosed
US-20120172300-A1 REMODELING AND GLYCOPEGYLATION OF FIBROBLAST GROWTH FACTOR (FGF) NOVO NORDISK A/S (DK) 2012-07-05 — — US disclosed
US-20120107867-A1 GLYCOPEGYLATED ERYTHROPOIETIN NOVO NORDISK A/S (DK) 2012-05-03 — — US disclosed
US-20110318780-A1 ENZYMATIC MODIFICATION OF GLYCOPEPTIDES BIOGENERIX AG (DE) 2011-12-29 — — US disclosed
US-20110003744-A1 Glycopegylated Erythropoietin Formulations NOVO NORDISK A/S (DK) 2011-01-06 — — US disclosed
US-20100330060-A1 GLYCOPEGYLATED FACTOR IX NOVO NORDISK A/S (DK) 2010-12-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130059780-A1 BRANCHED PEG REMODELING AND GLYCOSYLATION OF GLUCAGON-LIKE PEPTIDE-1 [GLP-1] GLP1R, GIPR, IAPP CD22 407/4885MAG 741/4885PSMB11 1082/4885
US-20160158319-A1 REMODELING AND GLYCOPEGYLATION OF FIBROBLAST GROWTH FACTOR (FGF) FGF2, FGF1, FGFR1 CD22 392/4885MAG 711/4885PSMB11 1992/4885
US-20120172300-A1 REMODELING AND GLYCOPEGYLATION OF FIBROBLAST GROWTH FACTOR (FGF) FGF2, FGF1, FGFR1 CD22 392/4885MAG 711/4885PSMB11 1992/4885
US-20100330060-A1 GLYCOPEGYLATED FACTOR IX F9, F13A1, F13B CD22 382/4885MAG 212/4885PSMB11 1335/4885
US-20160361427-A1 Glycopegylated Factor IX F9, F13A1, F13B CD22 514/4885MAG 234/4885PSMB11 1151/4885
US-20170136104-A1 GLYCOPEGYLATED FACTOR IX F9, F13A1, F13B CD22 514/4885MAG 234/4885PSMB11 1151/4885
US-20110003744-A1 Glycopegylated Erythropoietin Formulations EPOR, UGGT1, GNE CD22 375/4885MAG 298/4885PSMB11 1624/4885
US-20160184412-A1 Glycopegylated Factor IX F9, F13A1, F13B CD22 501/4885MAG 235/4885PSMB11 1158/4885
US-20170281785-A1 GLYCEROL LINKED PEGYLATED SUGARS AND GLYCOPEPTIDES UGCG, B3GAT3, UGGT1 CD22 367/4885MAG 119/4885PSMB11 2485/4885
US-20150125437-A1 Glycopegylated Factor IX F9, F13A1, F13B CD22 514/4885MAG 234/4885PSMB11 1151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback